about
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.Typhlitis complicating induction therapy in adult acute myeloid leukemia.Small-Sized Clone of T Cells in Multiple Myeloma Patient after Auto-SCT: T-LGL Leukemia Type or Clonal T-Cell Aberration?Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL?“Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”Pneumonia in Acute Leukemia Patients During Induction Therapy: Experience in a Single InstitutionEfficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple MyelomaParalytic ileus following "subcutaneous bortezomib" therapy: focus on the clinical emergency-report of two casesBendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moonActivity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myelomaSecondary plasma cell leukemia: a multicenter retrospective study of 101 patientsElotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
P50
Q39705915-5B5717A6-9986-4B4D-8621-9A34D91F18E6Q40095723-EEA7E6B0-8E19-416A-9F4F-A7A9F789DCBFQ40149390-48B9D1EB-54B4-4487-AC72-BAAA491750BCQ40577448-68452AEA-D3A7-4661-AC22-E7DFB389FA7CQ41842999-99BA35F6-8A64-43A9-B4FD-F0E3E8500E68Q48001581-7F40D5DE-7481-40BD-BBF5-1FCA91C93C7DQ48251589-639AD958-8F3C-4CFB-B8AF-EC9AB4379A6AQ48283707-B0E2D850-E367-421D-AECA-B0E8F62F9B8BQ48454388-A02C870A-3A68-442E-B62B-B8D7A67F60BCQ53262828-4FD3B847-C14B-4A70-9B6B-1CF680CB1988Q53557010-4A236948-C698-49A8-9629-F0F418ED2C70Q60171298-41D8BEC8-3BD5-4D7F-9462-EE97788AB2A0Q60171405-3854FA45-2CEF-4404-8EFD-2C45F8ABEC33Q60926803-53C869EC-8DAC-4559-8715-0860BB93C398Q86557156-F9C2D6BF-C0E5-47E4-9A97-44483548E864Q86657803-45300A07-778F-4F03-B952-7648C0CDF9BDQ87049505-5785542B-0996-4103-91FD-0516A9534541Q89386624-4D5F72FF-AE28-4367-8FE1-7EE956F89479Q89926240-BC4D9BA3-12B6-4EAE-ADF8-F67C868E8A64
P50
description
researcher ORCID ID=0000-0003-4813-8618
@en
wetenschapper
@nl
name
Giuseppe Mele
@en
Giuseppe Mele
@es
Giuseppe Mele
@nl
type
label
Giuseppe Mele
@en
Giuseppe Mele
@es
Giuseppe Mele
@nl
prefLabel
Giuseppe Mele
@en
Giuseppe Mele
@es
Giuseppe Mele
@nl
P106
P31
P496
0000-0003-4813-8618